Recent discoveries in molecular characterization of acute myeloid leukemia

Current Hematologic Malignancy Reports

Volumn 9, Issue 2, 2014, Pages 93-99

  Khasawneh, Mohamad K ^a   Abdel Wahab, Omar ^b  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; AML; Biomarkers; Molecular genetics; Mutational profiling; Prognosis; Targeted therapy

Indexed keywords

2 HYDROXYGLUTARIC ACID; BH3 PROTEIN; COHESIN; DNA METHYLTRANSFERASE 3A; INTERLEUKIN 2 RECEPTOR ALPHA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TUMOR MARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER RISK; CLINICAL PRACTICE; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; INTERMEDIATE RISK POPULATION; LOSS OF FUNCTION MUTATION; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; CLASSIFICATION; GENETICS; METABOLISM; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; PROCEDURES; PROGNOSIS;

DNA MUTATIONAL ANALYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84903618450     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0200-y     Document Type: Article

References (42)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453-74.
2. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acutemyeloid leukemia. N Engl J Med. 2008;358:1909-18. (Pubitemid 351620111)
3. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-9. (Pubitemid 43289355)
4. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904-11. (Pubitemid 46630738)
5. .• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424-33. This manuscript presents the initial identification of mutations in DNMT3A in AML as well as their clinical relevance. DNMT3A mutations are amongst the most common somatic mutations in AML and impart adverse prognostic impact (none of which was known until publication of this manuscript).
6. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43:309-15.
7. Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. Oncogene. 2010;29:3723-31.
8. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29:2889-96.
9. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058-66.
10. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339-44.
11. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225-34.
12. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118:409-12.
13. .• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079-89. This manuscript analyzed the clinical and therapeutic relevance of 18 recurrently mutated in genes in AML patients age 16-60 years-old uniformly treated on the ECOG E1900 study. The study identified genetic alterations which predicted for differential response to high-dose induction chemotherapy in AML.
14. Abbas S, Lugthart S, Kavelaars FG, et al. Acquiredmutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Blood. 2010;116:2122-6.
15. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:3636-43.
16. Green CL, Evans CM, Hills RK, Burnett AK, Linchl DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010;116(15):2779-82.
17. Ward PS, Cross JR, Lu C, et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene. 2012;31:2491-8.
18. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-301.
19. Abdel-Wahab O, Patel J, Levine RL. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin N Am. 2011;25:1119-33.
20. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553-67.
21. Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118:3803-10.
22. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European leukemianet risk classification of acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2011;29:1373-81.
23. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788-800.
24. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118:6920-9.
25. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97:388-92.
26. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:338-42.
27. Van Vlierberghe P, Patel J, Abdel-Wahab O, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25:130-4.
28. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121:4917-24.
29. Wang JH, Chen WL, Li JM, et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A. 2013;110:17017-22.
30. Janin M, Mylonas E, Saada V, et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the acute leukemia French Association Group. J Clin Oncol. 2013;32:297-305.
31. Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012;120:4649-52.
32. Gönen M, Sun Z, Figueroa ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012;120:2297-306.
33. Rockova V, Abbas S, Wouters BJ, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118:1069-76.
34. Pierceall WE, Kornblau SM, Carlson NE, et al. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013;12:2940-9.
35. .• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059-74. This manuscript presented whole genome and whole exome sequencing data from 200 AML patients, the largest study of its kind to date. The data from this study presents the most comprehensive list of recurrently mutated genes in AML at this time.
36. .• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64-9. This manuscript was the first paper to identify recurrent mutations in spliceosomal proteins in patients with myeloid malignancies. Subsequent studies have identified spliceosomal mutations in particular subsets of patients with MDS and chronic lymphocytic leukemia.
37. Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119:4480-5.
38. Rocquain J, Gelsi-Boyer V, Adelaide J, et al. Alteration of cohesin genes in myeloid diseases. Am J Hematol. 2010;85:717-9.
39. Bullinger L, Kronke J, Schon C, et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia. 2010;24:438-49.
40. Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A. 2009;106:12950-5.
41. Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013;45:1232-7.
42. Thol F, Bollin R, Gehlhaar M, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood. 2013;123:914-20.